Angiogenesis inhibitors for small cell lung cancer

被引：1

作者：

Song, Sang-Yun ^{[1
]}

Park, Cheol-Kyu ^{[1
]}

Oh, In-Jae ^{[1
]}

Kim, Young-Chul ^{[1
]}

机构：

[1] Chonnam Natl Univ, Lung & Esophageal Canc Clin, Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, Jeonnam, South Korea

来源：

TRANSLATIONAL CANCER RESEARCH | 2017年 / 6卷

关键词：

PHASE-II; BEVACIZUMAB; TRIAL; CISPLATIN; MULTICENTER; CARBOPLATIN; IRINOTECAN;

D O I：

10.21037/tcr.2017.04.22

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S539 / S540

页数：2

共 9 条

[1] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].

Antonia, Scott J. ;

Lopez-Martin, Jose A. ;

Bendell, Johanna ;

Ott, Patrick A. ;

Taylor, Matthew ;

Eder, Joseph Paul ;

Jaeger, Dirk ;

Pietanza, M. Catherine ;

Le, Dung T. ;

de Braud, Filippo ;

Morse, Michael A. ;

Ascierto, Paolo A. ;

Horn, Leora ;

Amin, Asim ;

Pillai, Rathi N. ;

Evans, Jeffry ;

Chau, Ian ;

Bono, Petri ;

Atmaca, Akin ;

Sharma, Padmanee ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Christensen, Olaf ;

Calvo, Emiliano .

LANCET ONCOLOGY, 2016, 17 (07) :883-895

[2] Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 [J].

Horn, Leora ;

Dahlberg, Suzanne E. ;

Sandler, Alan B. ;

Dowlati, Afshin ;

Moore, Dennis F. ;

Murren, John R. ;

Schiller, Joan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6006-6011

[3] Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study [J].

Ready, Neal E. ;

Dudek, Arkadiusz Z. ;

Pang, Herbert H. ;

Hodgson, Lydia D. ;

Graziano, Stephen L. ;

Green, Mark R. ;

Vokes, Everett E. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) :4436-4441

[4] Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) [J].

Reck, M. ;

von Pawel, J. ;

Zatloukal, P. ;

Ramlau, R. ;

Gorbounova, V. ;

Hirsh, V. ;

Leighl, N. ;

Mezger, J. ;

Archer, V. ;

Moore, N. ;

Manegold, C. .

ANNALS OF ONCOLOGY, 2010, 21 (09) :1804-1809

[5] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[6] Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial [J].

Spigel, David R. ;

Townley, Peter M. ;

Waterhouse, David M. ;

Fang, Liang ;

Adiguzel, Ibrahim ;

Huang, Jane E. ;

Karlin, David A. ;

Faoro, Leonardo ;

Scappaticci, Frank A. ;

Socinski, Mark A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2215-2222

[7] Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer [J].

Spigel, David R. ;

Greco, F. Anthony ;

Zubkus, John D. ;

Murphy, Patrick B. ;

Saez, Ruben A. ;

Farley, Cindy ;

Yardley, Denise A. ;

Burris, Howard A., III ;

Hainsworth, John D. .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) :1555-1560

[8]

Stefanou D, 2004, HISTOL HISTOPATHOL, V19, P37, DOI 10.14670/HH-19.37

[9] Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial [J].

Tiseo, Marcello ;

Boni, Luca ;

Ambrosio, Francesca ;

Camerini, Andrea ;

Baldini, Editta ;

Cinieri, Saverio ;

Brighenti, Matteo ;

Zanelli, Francesca ;

Defraia, Efisio ;

Chiari, Rita ;

Dazzi, Claudio ;

Tibaldi, Carmelo ;

Turolla, Gianni Michele ;

D'Alessandro, Vito ;

Zilembo, Nicoletta ;

Trolese, Anna Rita ;

Grossi, Francesco ;

Riccardi, Ferdinando ;

Ardizzoni, Andrea .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (12) :1281-+

← 1 →